Tiffany Groen, DO
Family Medicine · New Lenox, ILNPI 1609019538
Payments from drug & device makers
Across 158 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$712
- Novo Nordisk$680
- Phathom Pharmaceuticals, Inc.$299
- Astellas Pharma US Inc$290
- Lilly USA, LLC$288
- Exact Sciences$263
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,534100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $712 |
| Novo Nordisk | 36 | $680 |
| Phathom Pharmaceuticals, Inc. | 12 | $299 |
| Astellas Pharma US Inc | 13 | $290 |
| Lilly USA, LLC | 17 | $288 |
| Exact Sciences | 13 | $263 |
| Axsome Therapeutics, Inc. | 11 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $164 |
| Boehringer Ingelheim | 5 | $113 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| AstraZeneca | 4 | $60 |
| AbbVie | 2 | $56 |
| IBSA Pharma Inc. | 3 | $45 |
| Corcept Therapeutics | 2 | $43 |
| Novartis | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $27 |
| Viatris Specialty LLC | 1 | $27 |
| Agile Therapeutics, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| GSK | 1 | $16 |
| Baxter Healthcare | 1 | $13 |
How this compares
$3,543 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 57 | $86,732 |
| MounjaroTirzepatide | 57 | $60,893 |
| JardianceEmpagliflozin | 32 | $48,492 |
| EliquisApixaban | 28 | $29,004 |
| FarxigaDapagliflozin Propanediol | 22 | $27,653 |
| JanuviaSitagliptin Phosphate | 22 | $23,506 |
| MyrbetriqMirabegron | 29 | $22,641 |
| XareltoRivaroxaban | 14 | $22,186 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $21,739 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $19,342 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,026 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $17,586 |
| TrulicityDulaglutide | 19 | $17,305 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,411 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $680 | $86,73257 claims |
| Lilly USA, LLCMounjaro, Trulicity | $288 | $78,19876 claims |
| Boehringer IngelheimJardiance, Glyxambi | $113 | $70,23247 claims |
| PfizerEliquis, Paxlovid, Premarin | $712 | $34,21452 claims |
| AstraZenecaFarxiga | $60 | $27,65322 claims |
| Astellas Pharma US IncMyrbetriq | $290 | $22,64129 claims |
| Johnson & JohnsonXarelto | $18 | $22,18614 claims |
| GSKBreo Ellipta | $16 | $13,41127 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $4,211308 claims |
| AbbVieSynthroid | $56 | $2,16523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in New Lenox
- Mark ChristensenNew Lenox$2.1M
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.